Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses HyperAcute Renal (HAR) immunotherapy in patients with renal cell carcinoma (RCC).

In a phase I study of alpha-1, 3-galactosyltransferase-expressing allogeneic RCC immunotherapy, patients with metastatic RCC were given injections of HAR for 4 weeks (150 x106 cells/300 x106 cells intradermally). This was followed by 10 weeks of bi-weekly injections.

HAR was well tolerated in this population, says Hammers, and RCC was deemed an appropriate tumor type to target with combination immunotherapy.

View more from the 2017 Genitourinary Cancers Symposium

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Genitourinary Cancers

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research. 

Dr. Hammers on Study of HyperAcute Renal Immunotherapy in RCC